Recruiting

NCT Number: NCT05534009

Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)

The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Heinrich Heine university, Düsseldorf, Germany

About this study

Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from

HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific

objectives include:

to collect data and biological material from COVID-19 healthcare workers in 9 clinics from 8 countries and 3 continents.
Enrolment of HCW with an immunogenic event, either vaccination or infection.
Periodic collection of serum and whole blood every 4 months since enrolment and during 12-24 months (depending on how long immunity persists).
Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely:

Analyse the magnitude, breadth and duration of immunity following natural infection and/or vaccination.
Define the cross-immunity among the different viral variants.
Analyse the immune escape in a comprehensive set of combinations of vaccines and natural infection(s).
To accomplish the above objectives, WP2 will test:

Neutralising antibodies
Cellular immunity
Viral sequences

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The study subjects will be selected based on the following inclusion criteria:

Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
Having a signed informed consent when required by ethical approval

Exclusion criteria

NONE

Treatment and study plan

Follow up of the first known immunization event

Other

The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.

HCWs can be enrolled in the category of:

(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.

Primary outcomes

Number of HCW involved in the study

Time frame: through study completion, an average of 3 years

To collect the higher possible number of data and biological materials from the HCWs of the participating Units

Study contacts

Contact information is provided by the study sponsor or research team.

FRANCESCA INCARDONA, DR

CONTACT

[email protected]

+393356112830

Sponsors and collaborators

Lead sponsor

Euresist Network GEIE

Other

Collaborators

ASST Santi Paolo e Carlo
Bach Mai Hospital
Centro Hospitalar Lisboa Ocidental
Heinrich-Heine University, Duesseldorf
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus"
Istituto Europeo di Oncologia
Vilnius University Hospital Santaros Klinikos

Registry information

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2025
First posted: Sep 9, 2022
Registry last updated: Sep 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting